Metastatic colorectal cancer
Conditions
Interventions
TAS-102 treatment observation group:None
Sponsors
ShangHai ChangHai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Sign informed consent and join the study voluntarily; 2. Age >=18 years old; 3. Patients with unresectable metastatic colorectal adenocarcinoma confirmed by histopathology or cytology, with recurrence and progression after surgery or local therapy, may also be enrolled; 4. Progression or intolerance to at least second-line standard therapy, chemotherapy regimenincluding fluorouracil, oxaliplatin and irinotecan, bevacizumab or cetuximab Or refuse treatment with standard chemotherapy combined with bevacizumab or cetuximab; 5. Receiving TAS-102 (Suyuan) treatment; 6. The main organ functions meet the drug standards, namely: (1) Blood routine examination: a. Hemoglobin >=90g/L; b. Absolute neutrophil count >=1.5×10^9/L c. platelets >=75×10^9/L; (2) Biochemical examination: a. albumin >=20g/L;b. ALT and AST=30ml/min (Cockcroft-Gault formula).
Exclusion criteria
Exclusion criteria: 1. Confirmed pregnant or lactating women; 2. Patients who are participating in any clinical trial with an intervention outside of routine clinical practice; 3. Other situations deemed unsuitable for inclusion in the study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety Evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Overall Suvival, OS;Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactZhan Xianbao
ShangHai ChangHai Hospital
Outcome results
None listed